Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine
AssigneeTaiho Pharmaceutical Co., Ltd.
InventorsHarold Keer, Aram Oganesian, Kim-Hien Dao
Life of this patent
Estimating the term…
Abstract
Provided according to some embodiments of the invention are methods of treating cancer in a subject in need thereof that include administering to the subject a first amount of a hypomethylating agent (e.g., decitabine) and a first amount of cedazuridine in a first dosing cycle; measuring a response of the cancer to the first dosing cycle; and administering a second, reduced amount of the hypomethylating agent and a second, reduced amount of cedazuridine in subsequent dosing cycle(s) if the response of the cancer to the first dosing cycle meets a predetermined criterion.
Claims20
A method of treating cancer in a subject in need thereof, comprising:
- (i) administering to the subject a first amount of a hypomethylating agent (e.g., decitabine) and a first amount of cedazuridine in a first dosing cycle;
- (ii) measuring a response of the cancer to the first dosing cycle;
- and
- (iii) administering a second, reduced amount of the hypomethylating agent and a second, reduced amount of the cedazuridine in subsequent dosing cycle(s) if the response of the cancer measured in (ii) meets a predetermined criterion.
Dependencies are inferred from the claim text.